Multiple signaling pathways, structural proteins, and transcription factors are involved in the regulation of endothelial barrier function. The forkhead protein FOXF1 is a key transcriptional regulator of embryonic lung development, and we used a conditional knockout approach to examine the role of FOXF1 in adult lung homeostasis, injury, and repair. Tamoxifen-regulated deletion of both Foxf1 alleles in endothelial cells of adult mice (Pdgfb-iCreER/Foxf1 −/− ) caused lung inflammation and edema, leading to respiratory insufficiency and death. Deletion of a single Foxf1 allele made heterozygous Pdgfb-iCreER/Foxf1 +/− mice more susceptible to acute lung injury. FOXF1 abundance was decreased in pulmonary endothelial cells of human patients with acute lung injury. Gene expression analysis of pulmonary endothelial cells with homozygous FOXF1 deletion indicated reduced expression of genes critical for maintenance and regulation of adherens junctions. FOXF1 knockdown in vitro and in vivo disrupted adherens junctions, enhanced lung endothelial permeability, and increased the abundance of the mRNA and protein for sphingosine 1-phosphate receptor 1 (S1PR1), a key regulator of endothelial barrier function. Chromatin immunoprecipitation and luciferase reporter assays demonstrated that FOXF1 directly bound to and induced the transcriptional activity of the S1pr1 promoter. Pharmacological administration of S1P to injured Pdgfb-iCreER/Foxf1 +/− mice restored endothelial barrier function, decreased lung edema, and improved survival. Thus, FOXF1 promotes normal lung homeostasis and repair, in part, by enhancing endothelial barrier function through activation of the S1P/S1PR1 signaling pathway.
INTRODUCTION
Endothelial barrier function is critical for maintenance of normal alveolar homeostasis and lung repair after injury [reviewed in (1) ]. Pulmonary endothelial cells play a key role in maintaining the endothelial barrier and mediate the exchange of gases, water, and macromolecules between blood and surrounding alveolar tissue. Endothelial cells secrete various cytokines and chemokines that control hemostasis and immunologic and inflammatory events, regulate vascular tone, and promote interactions with inflammatory cells and neighboring vascular cell types. Acute lung injury (ALI) occurs in response to various insults, including pneumonia, sepsis, trauma, and mechanical ventilation, and is characterized by increased endothelial permeability, pulmonary edema, alveolar injury, and recruitment of inflammatory cells to the lung (2) . Acute respiratory distress syndrome (ARDS) is a life-threatening complication of ALI with a mortality rate of more than 35%, which accounts for about 75,000 deaths and 3.5 million hospital days per year in the United States (2, 3) . Given the lack of major improvements in the clinical management of ALI and ARDS, there is a compelling need for innovative molecular approaches to complement existing ALI and ARDS therapies.
Endothelial barrier function is regulated by various factors. Thrombin, bradykinin, histamine, reactive oxygen species (ROS), vascular endothelial growth factor (VEGF), tumor necrosis factor-a (TNF-a), and endotoxin increase endothelial permeability in cultured pulmonary endothelial cells and animals [reviewed in (1, 4) ]. In contrast, sphingosine 1-phosphate (S1P) and angiopoietin-1 (Ang-1) stabilize the endothelial barrier and decrease endothelial permeability (1) . S1P is a lysophospholipid mediator that circulates in the blood and maintains endothelial barrier function primarily through the S1PR1 receptor (4, 5) . Activation of S1PR1 by S1P substantially enhances the endothelial cell barrier through RacGTPasedependent cortical actin rearrangement (6) . S1pr1 −/− mice exhibit embryonic lethality due to impaired vasculogenesis (7) , implicating the S1pr1 gene in the development of blood vessels. In the adult lung, pharmacological inhibition of S1PR1 enhances pulmonary capillary leakage (8) . In zebrafish and mice, S1PR1 restricts angiogenic sprouting and ectopic vessel branch formation by stabilization of the VE-cadherin protein (9) . VE-cadherin is a key structural component of adherens junctions, cellular structures that play an important role in the maintenance of vascular integrity and lung repair after injury (1, 4) . S1P/S1PR1 signaling stabilizes VEcadherin and is required for proper maintenance and regulation of adherens junctions in endothelial cells.
The transcription factor forkhead box F1 (FOXF1) is a critical mediator of angiogenesis during lung embryonic development (10) (11) (12) (13) . Heterozygous deletions and point mutations in the Foxf1 gene locus are found in patients with alveolar capillary dysplasia with misalignment of pulmonary veins (ACD/MPV), a rare congenital disorder of neonates and infants characterized by severe defects in the development of the alveolar capillary network, lung hypoplasia, malposition of pulmonary veins, and hypoxemia. Because of the severity of developmental defects and progressive respiratory insufficiency in ACD/MPV infants, mortality usually occurs within the first month of life. Global deletion of Foxf1 in mice is embryonically lethal (12) . Mice heterozygous for the Foxf1 null allele (Foxf1 +/− alleles in endothelial cells in adult Pdgfb-iCreER/Foxf1 −/− mice caused uniform mortality due to severe pulmonary edema and increased lung inflammation, whereas deletion of only one Foxf1 allele was sufficient to increase the susceptibility of heterozygous Pdgfb-iCreER/Foxf1 +/− mice to ALI. In vitro and in vivo studies demonstrated that FOXF1 regulates endothelial barrier function through transcriptional activation of the S1pr1 promoter. Thus, FOXF1 is a key transcriptional regulator of endothelial cells and is essential for normal lung homeostasis and lung repair after injury.
RESULTS

Conditional deletion of Foxf1 from endothelial cells causes respiratory insufficiency and lethality in adult mice
To determine the role of FOXF1 in the adult lung, we generated conditional knockout mice with an inducible deletion of Foxf1 from endothelial cells. These mice contained the Pdgfb-iCreER transgene and two lungs revealed thickening of the alveolar septum, lung congestion, and severe inflammation in alveolar regions and pulmonary airways (Fig. 1A) . Pulmonary hemorrhage and fibrosis subsequently developed in Tamtreated endFoxf1 −/− mice, causing uniform mortality (Fig. 1, A and B ). There were no visible histological abnormalities in the hearts, livers, or kidneys of endFoxf1 fl/fl mice, and Tam-treated Pdgfb-iCreER mice, had normal lung histology (Fig. 1A and fig.  S1D ). To assess pulmonary edema, we measured the wet/dry weight ratio of lung tissue and the concentration of protein in bronchoalveolar lavage fluid (BALF) and found that both were significantly increased in Tam-treated endFoxf1 −/− mice compared to Tam-treated Foxf1 fl/fl controls (Fig. 1, C and D) . Airway compliance was reduced in endFoxf1 −/− mice, whereas airway resistance and respiratory elasticity were increased (Fig. 1E) , a finding consistent with increased stiffness of the lung tissue due to inflammation and edema. Thus, deletion of Foxf1 from endothelial cells of adult mice caused severe respiratory insufficiency, pulmonary edema, and mortality. S3C) . Furthermore, colocalization studies with endothelial cell-specific VE-cadherin (a membrane marker) and the transcription factor Erg (a nuclear marker) demonstrated that FOXF1 protein was present in the nuclei of alveolar endothelial cells and that Foxf1 deletion reduced FOXF1 staining (figs. S3D and S4D). Although FOXF1 was also detected in peribronchial smooth muscle cells, its abundance was unchanged in endFoxf1 −/− mice ( fig. S4B ). FOXF1 was not detected in alveolar macrophages ( fig. S1C ). Together, these data indicate that after Tam treatment, Pdgfb-iCreER efficiently and specifically deletes Foxf1 from the endothelial cells of adult lungs.
H&E
Deletion of Foxf1 resulted in the progressive accumulation of macrophages in lung tissue as shown by hematoxylin and eosin (H&E) staining ( Fig. 2A) and immunostaining for Mac-3 (Fig. 2, B and C). The number of macrophages was increased in BALF obtained from endFoxf1 −/− mice compared to that obtained from Foxf1 fl/fl controls (Fig. 2D ). The numbers of lymphocytes and neutrophils in BALF were not altered in endFoxf1 −/− mice (Fig. 2D ). Foxf1 mRNA abundance was about 60-fold higher in FACS-sorted pulmonary endothelial cells compared to those isolated from the liver or kidney ( fig. S2B ), suggesting that the lung phenotype in FOXF1-deficient mice is due to high Foxf1 expression in pulmonary endothelial cells. Finally, transplantation of wild-type bone marrow to irradiated endFoxf1 −/− mice did not influence lung inflammation or survival ( fig. S6 ). Thus, FOXF1 inactivation in resident lung endothelial cells causes respiratory insufficiency and mortality.
Foxf1 deletion from endothelial cells decreases the abundance of S1PR1
We compared genome-wide mRNA expression profiles between Tam-treated endFoxf1 −/− and control Foxf1 fl/fl lungs. RNA sequencing (RNA-seq) analysis identified 1137 genes with decreased expression and 1417 genes with increased expression after deletion of Foxf1 (Fig. 3A and table S1 ). Genes in the "biological adhesion" and "cell-substrate adhesion" functional categories showed the greatest suppression among genes with decreased expression in endFoxf1 −/− lungs (Fig. 3B ). Among the genes showing increased expression in endFoxf1 −/− lungs, "leukocyte migration" and "inflammatory response" were the most enriched functional classes (Fig. 3B ). Foxf1 mRNA was decreased 7.7-fold in endFoxf1 −/− lungs ( Fig. 3C ), confirming the quantitative reverse transcription polymerase chain reaction (qRT-PCR) data ( fig. S3A ). The expression of IL6 [which encodes interleukin (IL)-6], Ccl2 [which encodes chemokine CC motif ligand (CCL) 2], Ccl7 (which encodes CCL7), IL33 (which encodes IL-33), and Sele (which encodes E-selectin) was increased in endFoxf1 −/− lungs ( Fig. 3C ), findings consistent with increased lung inflammation. In contrast, endFoxf1 −/− lungs exhibited decreased expression of genes critical for structural integrity and regulation of endothelial cell junctions, such as S1pr1 (which encodes S1PR1), Clnd5 (which encodes claudin-5), Ctnna1 (which encodes a-catenin1), Ctnnd1 (which encodes d-catenin1), Vcl (which encodes vinculin), Jup (which encodes junction plakoglobin), Actn1 (which encodes a-actinin), Lima1 (which encodes LIM domain and actin-binding protein 1), and Cdh5 (which encodes VE-cadherin) (Fig.  3C ). The expression of these seven genes was confirmed by qRT-PCR analysis of total lung RNA (Fig. 3D ). Because S1P/S1PR1 signaling enhances endothelial barrier function (1, 4), reduced S1PR1 abundance could contribute to edema and inflammation in endFoxf1 −/− lungs. Therefore, we focused our next studies on the regulation of S1pr1 gene expression by FOXF1. S1pr1 mRNA was decreased in Tam S3A ). Western blot and immunostaining of lung sections showed decreased abundance of S1PR1 and one of its targets, VE-cadherin (figs. S4D and S7, B and C). To determine whether changes in S1PR1 occurred specifically in endothelial cells, FACS-sorted pulmonary endothelial cells were isolated at day 3 after Tam treatment, a time point before edema and inflammation in endFoxf1
lungs. Reduced Foxf1 mRNA abundance was associated with decreased S1pr1 in FACSsorted endothelial cells (Fig. 3 , E and F), suggesting that FOXF1 directly or indirectly regulates the expression of the S1pr1 gene.
Foxf1 deletion from endothelial cells increases endothelial permeability
Because S1P/S1PR1 signaling is essential for structural integrity and regulation of adherens junctions in pulmonary endothelial cells (1, 4), we assessed vascular permeability in Tam-treated endFoxf1 −/− lungs. BALF was collected after the injection of Evans blue dye into endFoxf1 −/− and control Foxf1 fl/fl mice. Increased amounts of Evans blue dye were found in BALF from endFoxf1 −/− mice at day 6 and day 15 after Tam administration (Fig. 4A, left panel) . FOXF1-deficient lungs retained Evans blue dye after extensive perfusion of blood vessels with saline (Fig. 4A, right panel) , indicating vascular leak into the lung tissue. These results show that deletion of Foxf1 from endothelial cells increased vascular permeability in the adult lung.
The effect of FOXF1 inhibition on endothelial barrier function was also analyzed in vitro using cell monolayers of human umbilical vein endothelial cells (HUVECs). FOXF1 was knocked down in HUVECs by a lentivirus containing a FOXF1-specific short hairpin RNA (shRNA), which efficiently reduced Foxf1 mRNA (Fig. 4B ) and decreased FOXF1 protein staining in nuclei of HUVECs (Fig. 4C) . Similar to in vivo data, knockdown of FOXF1 reduced S1pr1 and Cdh5 mRNAs lungs (n = 3 mice per genotype). *P < 0.05; ***P < 0.001. SSC-A, side-scatter area; FSC-A, forwardscatter area.
( Fig. 4B) . Accumulation of VE-cadherin protein at adherens junctions was decreased in FOXF1-deficient cells (Fig. 4D) . To measure endothelial permeability, Evans blue dye-labeled albumin was added to the top chamber containing a complete monolayer of HUVECs. The albumin leak to the lower chamber was subsequently measured. Knockdown of FOXF1 increased albumin leakage through the HUVEC monolayer (Fig. 4E) (Fig. 4F) . The lack of changes in cell survival and metabolic activity was confirmed by colorimetric measurement of WST-1 reagent (Fig. 4G) . The abundance of the mRNAs of the apoptotic markers Bcl2 and Bax was not altered after depletion of FOXF1 (Fig. 4B) . Six days after Tam treatment, endFoxf1 (Fig. 5, A and B) . However, at day 15 after Tam treatment, increased apoptosis was observed in endFoxf1 −/− lungs (Fig. 5C ). Despite increased apoptosis, cleaved caspase-3 was not detected in endothelial cells of Tam-treated endFoxf1 −/− lungs (Fig. 5C) . Thus, knockdown of FOXF1 in vitro and in vivo reduced S1PR1 abundance, decreased the accumulation of VE-cadherin in cell junctions, and impaired endothelial barrier function.
FOXF1 directly binds to and induces the transcriptional activities of the S1pr1 and Cdh5 promoters Because FOXF1 deficiency was associated with decreased S1PR1 expression in vivo and in vitro, we investigated whether FOXF1 directly regulates the S1pr1 promoter. Four potential FOXF1 binding sites were identified in the −6.0-kb promoter region of the mouse S1pr1 gene. Chromatin immunoprecipitation (ChIP) was performed using mouse lung tissue to determine whether FOXF1 protein physically bound to the S1pr1 promoter. qPCR was used to identify specific DNA promoter fragments that interacted with FOXF1. FOXF1 specifically bound to the −3880/−3876-base pair (bp) and −5141/−4815-bp regions of the S1pr1 promoter that contain FOXF1 binding sites (Fig. 6A) . FOXF1 did not bind to the Hoxa11 genomic DNA or the −2772/−2759-bp S1pr1 promoter region that lacks FOXF1 binding sites (Fig. 6A) . In endothelial MFLM-91U cells, overexpressed FOXF1 transcriptionally activated a reporter containing the S1pr1 promoter fused to luciferase (Fig. 6B) . Furthermore, FOXF1 directly bound to and transcriptionally activated the mouse VEcadherin (Cdh5) promoter through the −788/−775-bp promoter region (Fig. 6, C and D) . FOXF1 did not bind to the Cldn5 promoter in spite of the presence of two potential FOXF1 binding sites in the −2451/−2439-bp and −1818/−1806-bp Cldn5 promoter regions (Fig. 6E) . These data indicate that S1pr1 and Cdh5 are direct transcriptional targets of FOXF1 in endothelial cells.
Heterozygous endFoxf1
+/− mice exhibit increased susceptibility to butylated hydroxytoluene-induced lung injury
We next examined FOXF1 requirements during lung injury and repair. Because homozygous endFoxf1 −/− mice developed lung edema and inflammation without exogenous insults (Figs. 1 and 2) , we used heterozygous endFoxf1 +/− mice in which only one Foxf1 allele was deleted from endothelial cells. Tam-treated endFoxf1 +/− mice were phenotypically normal and exhibited normal lung histology (Fig. 7A) . After lung injury was induced by butylated hydroxytoluene (BHT), 85% of Tam-treated endFoxf1 +/− mice, but none of the Tam-treated Foxf1 +/fl controls, had respiratory insufficiency and mortality (Fig. 7B) . Pulmonary inflammation was more severe in BHTtreated endFoxf1 +/− mice compared to controls (Fig. 7 , C to E). The amount of Evans blue dye was increased in the BALF and lung tissue of BHTtreated endFoxf1 +/− mice (Fig. 7F) . Although Foxf1 mRNA was decreased after BHT treatment in both groups of mice, these changes were more prominent in endFoxf1 +/− lungs (Fig. 7C) . S1pr1 mRNA was lower in BHT-treated endFoxf1 +/− lungs (Fig. 7C) , a finding consistent with the transcriptional activation of the S1pr1 promoter by FOXF1 (Fig. 6) . Moreover, FOXF1 staining was decreased in pulmonary endothelial cells from patients with severe bacterial pneumonia (Fig. 7G) , suggesting that FOXF1 plays a role in lung injury and repair in humans. Together, our results indicate that endothelial cell-specific deletion of only one Foxf1 allele was sufficient to increase susceptibility of adult mice to BHTmediated lung injury.
Pharmacological treatment with S1P prevents mortality and reduces vascular permeability in BHT-treated endFoxf1 +/− mice To determine whether diminished S1P/S1PR1 signaling contributes to increased susceptibility of FOXF1-deficient mice to BHT lung injury, we used S1P to induce S1P/S1PR1 signaling in vivo. Two tail vein injections of S1P significantly decreased mortality in heterozygous endFoxf1 Apoptosis was not detected in endothelial cells (arrowheads) (n = 3 mice per genotype). Scale bars, 50 mm.
mice after BHT injury (Fig. 7B and fig. S8 ). Administration of S1P reduced the number of macrophages in BHT-treated endFoxf1 +/− lungs to that seen in BHT-treated Foxf1 +/fl controls (Fig. 7, D and E) . S1P also decreased the accumulation of Evans blue dye in the BALF and lung tissue of BHT-treated endFoxf1 +/− mice (Fig. 7F) . Thus, S1P improved endothelial barrier function and reduced lung inflammation in BHTinjured endFoxf1 +/− mice. S1P treatment did not increase the survival of homozygous endFoxf1 −/− mice ( fig. S9, A and B) , most likely due to the contribution of other FOXF1 target genes to the endFoxf1 −/− phenotype. Similar to BHT-induced lung injury, intratracheal administration of lipopolysaccharide (LPS) increased the number of inflammatory cells in the BALF and lung tissue of endFoxf1 +/− mice ( fig. S10, A and B) . The S1PR1-selective agonist CYM5442 attenuated lung inflammation in LPStreated endFoxf1 +/− mice ( fig. S10, A and B) . Thus, S1pr1 is an important transcriptional target of FOXF1 in the adult lung, and the increased susceptibility of endFoxf1 +/− mice to lung injury could be ameliorated by pharmacological administration of S1P or CYM5442. DISCUSSION S1P maintains endothelial barrier integrity by binding to the S1PR1 receptor, causing RacGTPase-dependent cortical actin rearrangement (1, 6) . Although S1PR2 and S1PR3 are also present in endothelial cells, the barrierenhancing property of S1P is mainly mediated through S1PR1. A stable knockdown of S1PR1 disrupts adherens junctions and decreases VE-cadherin abundance in HUVECs after LPS and TNF-a stimulation (18) . S1P/S1PR1 stimulation inhibits vascular permeability and alveolar flooding in preclinical animal models of ALI (19) , demonstrating that activation of the S1P/S1PR1 signaling pathway could be beneficial in patients with ALI and ARDS. Although both signal transducer and activator of transcription 3 (STAT3) and Krüppel-like factor 2 (KLF2) can transcriptionally activate the S1pr1 promoter in tumor cells and T lymphocytes (20, 21) , neither STAT3 nor KLF2 is active in endothelial cells of quiescent lungs where S1pr1 is robustly expressed. Therefore, other transcriptional regulators must be involved in the maintenance of S1pr1 transcription during normal lung homeostasis. An important contribution of the present study is that FOXF1 induced S1pr1 transcription in both quiescent and injured lungs, suggesting that FOXF1 is a major regulator of S1P/S1PR1 signaling in endothelial cells. FOXF1 regulation of S1PR1 appears to be at the transcriptional level, as supported by ChIP analysis and luciferase reporter assays using the S1pr1 promoter. Genetic ablation of FOXF1 in purified endothelial cells caused a 50% reduction in S1pr1 mRNA. These data suggest that the S1pr1 gene is regulated by other endothelial transcription factors in addition to FOXF1.
VE-cadherin is a key structural component of adherens junctions and critical for the maintenance and regulation of vascular integrity during embryonic development, lung repair, and alveolar homeostasis (1, 4) . VE-cadherin controls vascular permeability and inhibits unrestrained vascular growth (22) . Several barrier-destabilizing mediators, such as thrombin and VEGF, increase endothelial permeability through VE-cadherin endocytosis and degradation (1) . Our data suggest that FOXF1 maintains endothelial barrier function in pulmonary endothelial cells, at least in part, by activating the Cdh5 promoter upstream of the gene encoding VE-cadherin. Furthermore, we showed that FOXF1 induces endothelial barrier function through transcriptional induction of the S1pr1 promoter, which, in turn, causes activation of S1P/S1PR1 signaling and stabilization of VE-cadherin in endothelial junctions. Pharmacological administration of S1P to BHT-injured endFoxf1 +/− mice improved survival after BHT injury, providing direct support to our concept. Whereas S1P/S1PR1 signaling is important for endothelial barrier function, endothelial cell-specific inactivation of S1pr1 or inhibition of plasma S1P does not cause lethality in adult mice (23) (24) (25) . Here, we found that FOXF1 inactivation in endothelial cells disrupted the expression of multiple genes in addition to S1pr1 and Cdh5. These include genes encoding structural proteins of endothelial cell junctions and proinflammatory regulators. Therefore, it is likely that respiratory insufficiency and lethality in FOXF1-deficient mice occur as a result of simultaneous disruption in the expression of many endothelial genes. We previously demonstrated that FOXF1 induces transcription of Vegf receptor genes in embryonic endothelial cells of the yolk sac (10) . Surprisingly, we found no differences in Flk1 and Flt1 mRNAs in adult endothelial cells after inactivation of FOXF1 (table 1) . These results suggest that FOXF1 has different functions in embryonic endothelial cells as compared to adult endothelial cells. It is possible that distinct coactivator proteins alter the transcriptional effects of FOXF1, depending on tissue specificity or developmental status. RNA-seq analysis of FOXF1-deficient mouse lungs revealed an increase in mRNAs encoding proinflammatory mediators, such as IL6, Ccl2, and IL33. Given the important role of CCL2 and IL-6 in macrophage recruitment during lung injury, these findings are consistent with the increased numbers of macrophages in the BALF and lung tissue of FOXF1-deficient mice. It is possible that macrophage-produced proinflammatory mediators further exacerbate lung edema and inflammation, contributing to mortality in endFoxf1 −/− mice. Although apoptosis was increased in endFoxf1 −/− lungs, most apoptotic cells were nonendothelial cells. These data suggest that the increased apoptosis was a consequence of edema and inflammation in FOXF1-deficient lungs. Because IL-6 and IL-33 increase endothelial permeability in cultured endothelial cells and in vivo (26, 27) , high concentrations of these proinflammatory mediators can contribute to increased endothelial permeability in FOXF1-deficient mice.
In summary, FOXF1 is a critical transcriptional regulator of pulmonary endothelial cells and is required for maintenance of endothelial barrier function during normal alveolar homeostasis and lung repair after injury. Discovery of small-molecule compounds that activate or stabilize FOXF1 protein could provide novel treatments for patients with ALI and ARDS.
MATERIALS AND METHODS
Mice, experimental lung injury, and measurement of endothelial permeability
Foxf1
fl/fl mouse line was previously generated and bred into the C57Bl/6 mouse background (10) . ) mice. Tam (3 mg; Sigma) was given as oral gavage. Evans blue dye (50 mg/kg) was injected intraperitoneally, and BALF was collected 4 hours after injection. The vasculature was perfused with saline to remove intravascular Evans blue dye. The concentration of Evans blue dye was determined by measuring the absorbance at 620 and 740 nm and normalized to a standard curve of known Evans blue dye concentrations. Lung injury was induced by a single intraperitoneal injection of BHT (3,5-di-tert-butyl-4-hydroxytoluene; 200 mg/kg per body weight; Sigma) diluted in corn oil as described (16) Mice were harvested at day 6 after BHT administration. Tam was given 5 days before BHT treatment. For the S1P rescue experiment, Tam-treated endFoxf1 +/− and control mice were intravenously injected with S1P (20 nmol per mouse; Sigma) or vehicle (saline) on days 2 and 8 after BHT treatment. LPS (10 mg per mouse; catalog no. L3012-5G, Sigma) was given intratracheally on days 3, 5, and 7 after Tam administration. CYM5442 (10 mg/kg per body weight; Tocris) was given intraperitoneally on days 6, 7, 8, and 9 after Tam treatment, and mice were harvested on day 10. A flexiVent computer-controlled small animal ventilator was used to measure lung function as previously described (28, 29) . All animal studies were approved by the Animal Care and Use Committee of Cincinnati Children's Research Foundation.
Histology and immunostaining
Lung paraffin sections were used for H&E staining or immunohistochemistry as previously described (30, 31) . The following antibodies were used for immunostaining: FOXF1 [1:1000; (10)], Mac-3 (1:1500; #553322, BD Pharmingen), Pecam-1 (1:500; #553370, BD Pharmingen), Erg-1/2/3 (1:200; #sc-353, Santa Cruz Biotechnology), b-catenin (1:300; #sc-7199 or #sc-1496, Santa Cruz Biotechnology), VE-cadherin (1:200, #sc-6458, Santa Cruz Biotechnology), and S1P 1 /EDG-1 (1:100; #MAB7089, R&D Systems). Antibody-antigen complexes were detected using biotinylated secondary antibody followed by avidin-biotin-horseradish peroxidase complex and 3,3′-diaminobenzidine substrate (Vector Labs), as previously described (16, 32, 33) . Sections were counterstained with nuclear fast red (Vector Labs). For immunofluorescence imaging, secondary antibodies conjugated with Alexa Fluor 488 or Alexa Fluor 594 (Invitrogen/Molecular Probes) were used as described (34, 35) . Cell nuclei were counterstained with DAPI. Rhodamine phalloidin (1:1000; #R415, Molecular Probes) was used to visualize F-actin. Images were obtained using a Zeiss AxioPlan 2 microscope.
Flow cytometry and measurement of apoptosis
Flow cytometry was performed using enzyme-digested lung tissue as previously described (29, 36, 37) . Apoptotic endothelial cells were detected by the annexin Vapoptosis detection kit APC (eBioscience). 7AAD (eBioscience) was used to label necrotic cells. Antibodies against CD31 (Pecam-1), CD45, and CD326 were purchased from eBioscience. Stained cells were analyzed using a BD FACSCanto III flow cytometer. The WST-1 reagent was purchased from Roche and used according to the manufacturer's instructions.
Cell culture, qRT-PCR, and Western blot
The MISSION shRNA Lentiviral system (Sigma-Aldrich) was used to knock down FOXF1 in HUVECs (Lonza) according to the manufacturer's instructions. For all experiments, HUVECs were used in passages 3 to 6. Evans blue dye-labeled albumin was used to measure permeability in confluent monolayers of HUVECs as previously described (38) . Evans blue dye-labeled albumin leak was measured as a flux of albumin in nanograms per minute using a standard curve of known albumin concentrations. mRNAs of specific genes were measured by qRT-PCR using TaqMan probes (table S2) and the StepOnePlus Real-Time PCR system (Applied Biosystems) as described (31, 39) . RNeasy Mini kit (Qiagen) was used to isolate the total RNA from endothelial cells. Western blot was performed using Pierce ECL Western blotting substrate (Thermo Scientific) as described (40, 41) .
ChIP, dual-luciferase assay, and RNA-seq analysis Lung tissue from Tam-treated endFoxf1 −/− and control Foxf1 fl/fl mice was cross-linked by formaldehyde. ChIP was performed using a FOXF1 antibody (10) . Chromatin DNA fragments were 500 to 1000 bp in size. Reverse cross-linked ChIP DNA samples were subjected to qPCR using primers specific to promoter regions of murine S1pr1, Cdh5, and Cldn5 genes (table S3) . Primers specific to the HoxA11 gene were used as a negative control. DNA binding was normalized to control ChIP DNA samples, which were immunoprecipitated using IgG control antibody (42) . Luciferase reporters driven by the S1pr1 and Cdh5 promoters were generated by PCR amplification of mouse genomic DNA (primers are listed in table S3) followed by cloning of the DNA fragments into pGL2-Basic firefly luciferase plasmid (Promega) as described (43) . FOXF1 mammalian expression construct (CMV-FOXF1) was previously described (44, 45) . CMV-Renilla was used as an internal control to normalize transfection efficiency. Dual luciferase assay (Promega) was performed in MFLM-91U cells as described previously (32, 43) . For RNA-seq analysis, RNA was isolated from endFoxf1 −/− and control Foxf1 fl/fl lungs at day 6 after Tam administration. Differentially expressed genes were identified using DESeq, and P value was calculated using the c 2 likelihood ratio test in Agilent GeneSpring GX suite (46) . Genes with expression altered by a factor of 1.5 in endFoxf1 −/− lungs were selected for gene set enrichment analysis using ToppGene Suite (47) . The statistical significance of each bioprocess was calculated using negative log 2 transformation of P value. Heat map was constructed on differentially expressed genes using JMP Genomics 6.0.
Statistical analysis
Statistical analysis was performed using Prism software. Student's t test and one-way analysis of variance (ANOVA) were used to determine statistical significance. Right-skewed measurements were log-transformed to meet normality assumption before analyses. P < 0.05 was considered significant. Values for all measurements were expressed as means ± SEM. KaplanMeier estimate of survival distribution of two groups was also computed.
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